![Martin Edwards](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Martin Edwards
Direttore/Membro del Consiglio presso
Tarsa Therapeutics, Inc.
Profilo
Martin W.
Edwards was the founder of Epsilon-3 Bio Ltd, serving as Chairman since 2010 to 2016.
Dr. Edwards is currently a Director at Vantia Ltd. since 2008, Tarsa Therapeutics, Inc., Nuvelution Pharma, Inc., Morphic Therapeutic, Inc., Stargazer Pharmaceuticals, Inc., and a Member of The Royal College of Physicians and the Royal College of General Practitioners.
Former positions include Chief Executive Officer at ReNeuron Group Plc and ReNeuron Ltd. from 1998 to 2003, Chairman at Symphogen A, Chairman at KalVista Pharmaceuticals Ltd., Chairman at KalVista Pharmaceuticals, Inc. from 2019 to 2022, Independent Director at Reata Pharmaceuticals, Inc. from 2020 to 2023, and Director at Thiakis Ltd., Logical Therapeutics, Inc., F2G Ltd., Serentis Ltd., Acacia Pharma Ltd., The Bioindustry Association, Funxional Therapeutics Ltd., NeRRe Therapeutics Ltd., Acacia Pharma Group Ltd., Harmony Biosciences Holdings, Inc., and Harmony Biosciences LLC.
Additional former roles include Independent Non-Executive Director at Verona Pharma Plc from 2019 to 2025, Independent Director at Inozyme Pharma, Inc. from 2017 to 2025, Non-Executive Director at Karus Therapeutics Ltd., Independent Director at Morphic Holding, Inc. from 2020 to 2024, Independent Director at CoLucid Pharmaceuticals, Inc. from 2015 to 2017, Vice President-Pharmacology & Medical Affairs at ZymoGenetics, Inc. from 1989 to 1992, Vice President & Head-Drug Development at Novo Nordisk A, Senior Vice President-Medical Affairs at Novo Nordisk, Inc. from 1992 to 1998, Senior Partner at Novo Holdings A from 2003 to 2009, and Senior Partner at Novo Ventures 1 A from 2014 to 2020.
Education includes undergraduate and doctorate degrees from The University of Manchester and an MBA from the University of Warwick.
Posizioni attive di Martin Edwards
| Società | Posizione | Inizio |
|---|---|---|
Tarsa Therapeutics, Inc.
 Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel oral treatment for post-menopausal osteoporosis | Direttore/Membro del Consiglio | - |
Stargazer Pharmaceuticals, Inc.
 Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical drugs | Direttore/Membro del Consiglio | - |
The Royal College of Physicians
 The Royal College of Physicians Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Royal College of General Practitioners
 Royal College of General Practitioners Other Consumer ServicesConsumer Services College/University | Corporate Officer/Principal | - |
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Researches and develops small molecules to block transmembrane integrin receptors | Direttore/Membro del Consiglio | - |
Novo Holdings A/S (Denmark)
 Novo Holdings A/S (Denmark) Investment ManagersFinance Functions as an alternative investment manager | Investitore di Private Equity | - |
Precedenti posizioni note di Martin Edwards
| Società | Posizione | Fine |
|---|---|---|
| VERONA PHARMA PLC | Direttore/Membro del Consiglio | 07/10/2025 |
| INOZYME PHARMA, INC. | Direttore/Membro del Consiglio | 01/07/2025 |
| MORC HOLD | Direttore/Membro del Consiglio | 16/08/2024 |
| ░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Martin Edwards
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
68
Relazioni di 1° grado
39
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 39 |
|---|---|
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein based drugs | Health Technology |
Novo Nordisk A/S
 Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
ReNeuron Group Plc
 ReNeuron Group Plc Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops and manufactures cell-based therapy products | Health Technology |
CoLucid Pharmaceuticals, Inc.
 CoLucid Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for neurological disorders | Health Technology |
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics which regulates cellular metabolism and inflammation in serious neurologic diseases | Health Technology |
Thiakis Ltd.
 Thiakis Ltd. BiotechnologyHealth Technology Develops novel analogues of naturally occurring hormones for the treatment of obesity and co-morbidities | Health Technology |
Novo Holdings A/S (Denmark)
Novo Holdings A/S (Denmark) Investment ManagersFinance Functions as an alternative investment manager | Finance |
The University of Manchester
 The University of Manchester Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ReNeuron Ltd.
 ReNeuron Ltd. BiotechnologyHealth Technology Researches and develops drugs, diagnostics and other therapeutic products | Health Technology |
University of Warwick
 University of Warwick Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Karus Therapeutics Ltd.
 Karus Therapeutics Ltd. BiotechnologyHealth Technology Provides therapies for treatment of cancer and inflammatory diseases | Health Technology |
Scandinavian International Management Institute
 Scandinavian International Management Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Verona Pharma Plc
 Verona Pharma Plc Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of allergic rhinitis and other chronic respiratory diseases | Health Technology |
The Royal College of Physicians
The Royal College of Physicians Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Develops biological medicines | Health Technology |
Logical Therapeutics, Inc.
 Logical Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops products that treat diseases associated with inflammation | Health Technology |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology Engages in research and development of novel drugs for life-threatening systemic fungal diseases treatment | Health Technology |
Symphogen A/S
 Symphogen A/S BiotechnologyHealth Technology Develops antibody therapeutics for the treatment of cancers | Health Technology |
Serentis Ltd.
 Serentis Ltd. Pharmaceuticals: MajorHealth Technology Discovers, develops and distributes pharmaceutical products | Health Technology |
Acacia Pharma Ltd.
 Acacia Pharma Ltd. Pharmaceuticals: MajorHealth Technology Provides supportive care product opportunities for post-surgical and cancer patients | Health Technology |
The Bioindustry Association
 The Bioindustry Association Miscellaneous Commercial ServicesCommercial Services Operates as a association to encourage and promote bioscience sector | Commercial Services |
Vantia Ltd.
 Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Provides molecule agonists of vasopressin receptors | Commercial Services |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures invests in companies located in Europe, the United States and Asia. The firm targets companies operating in the fields of health technology, health services, biotechnology and medical specialties sectors. It provides financing for early stage capital requirements. | Finance |
Funxional Therapeutics Ltd.
 Funxional Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Provides drug and therapeutical development services | Health Technology |
Tarsa Therapeutics, Inc.
Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel oral treatment for post-menopausal osteoporosis | Health Technology |
Royal College of General Practitioners
Royal College of General Practitioners Other Consumer ServicesConsumer Services College/University | Consumer Services |
KalVista Pharmaceuticals Ltd.
 KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops oral medicines | Health Technology |
Epsilon-3 Bio Ltd
 Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Provides compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders | Health Technology |
NeRRe Therapeutics Ltd.
 NeRRe Therapeutics Ltd. Medical DistributorsDistribution Services Provides clinical and pre clinical drugs for treatment of neuronal hypersensitivity | Distribution Services |
Nuvelution Pharma, Inc.
 Nuvelution Pharma, Inc. BiotechnologyHealth Technology Provides solutions for R&D companies in the pharmaceutical and biotech industries | Health Technology |
Acacia Pharma Group Ltd.
 Acacia Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company that engages in developing and commercializing novel products for surgery, invasive procedures & chemotherapy | Health Technology |
Morphic Therapeutic, Inc.
Morphic Therapeutic, Inc. BiotechnologyHealth Technology Researches and develops small molecules to block transmembrane integrin receptors | Health Technology |
Morphic Holding, Inc.
 Morphic Holding, Inc. Pharmaceuticals: MajorHealth Technology Develops oral integrin drugs | Health Technology |
KalVista Pharmaceuticals, Inc.
 KalVista Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets small molecule protease inhibitors for diseases | Health Technology |
Inozyme Pharma, Inc.
 Inozyme Pharma, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines | Health Technology |
Novo Holdings A/S (Investment Company)
 Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings-IC aims to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. The firm invests in almost all life science segments including pharmaceuticals, biotechnology, medical technology, healthcare services and industrial BioSolutions. Outside of the life sciences they invest in a diversified portfolio of equities, fixed income, real assets and alternatives. | Finance |
Harmony Biosciences Holdings, Inc.
 Harmony Biosciences Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapies for patients living with rare neurological disorders | Health Technology |
Harmony Biosciences LLC
 Harmony Biosciences LLC Pharmaceuticals: MajorHealth Technology Develops and commercializes therapies for people living with rare neurological disorders | Health Technology |
Stargazer Pharmaceuticals, Inc.
Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical drugs | Health Technology |
